Associate Professor Eva Segelov and Associate Professor Trevor Leong have been selected for an oral presentation on the AGITG ICECREAM and TOPGEAR study at the European Society for Medical Oncology Congress September, 25 – 29 in Vienna.
Eva’s presentation is on Monday 28, 10:35am in Hall A1: The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.
Trevor’s presentation is on Tuesday 29, 8:30am in Hall C2: TOPGEAR: A randomized phase II/III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC
‘The European Cancer Congress will provide ideal surroundings for participants to leverage knowledge, promote education and build awareness about oncology-placing the patient at the heart of all our efforts and discussions.’
For more information about the Congress, click here